• +1-646-491-9876
    • +91-20-67278686

    Search

    African Trypanosomiasis - Pipeline Review, H1 2017

    African Trypanosomiasis - Pipeline Review, H1 2017

    • Report Code ID: RW0001709492
    • Category Pharmaceuticals
    • No. of Pages 46
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    African Trypanosomiasis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide African Trypanosomiasis - Pipeline Review, H1 2017, provides an overview of the African Trypanosomiasis (Infectious Disease) pipeline landscape.

    African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable) , sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness. Treatment includes anti-protozoal agents.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide African Trypanosomiasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The African Trypanosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 3 molecules, respectively.

    African Trypanosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of African Trypanosomiasis (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in African Trypanosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates African Trypanosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for African Trypanosomiasis (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for African Trypanosomiasis (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding African Trypanosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    African Trypanosomiasis - Overview
    African Trypanosomiasis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    African Trypanosomiasis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    African Trypanosomiasis - Companies Involved in Therapeutics Development
    Incuron LLC
    Novartis AG
    Sanofi
    Scynexis Inc
    African Trypanosomiasis - Drug Profiles
    AN-5568 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CBL-0137 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DDD-100097 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fexinidazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GNF-6702 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    melarsoprol hydroxypropylbetadex - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MS-08 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides for Sleeping Sickness - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for African Trypanosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Sleeping Sickness - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Variant Surface Glycoprotein for African Trypanosomiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    African Trypanosomiasis - Dormant Projects
    African Trypanosomiasis - Discontinued Products
    African Trypanosomiasis - Product Development Milestones
    Featured News & Press Releases
    Aug 30, 2016: UGA researchers discover a drug for a tropical disease
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for African Trypanosomiasis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    African Trypanosomiasis - Pipeline by Incuron LLC, H1 2017
    African Trypanosomiasis - Pipeline by Novartis AG, H1 2017
    African Trypanosomiasis - Pipeline by Sanofi, H1 2017
    African Trypanosomiasis - Pipeline by Scynexis Inc, H1 2017
    African Trypanosomiasis - Dormant Projects, H1 2017
    African Trypanosomiasis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for African Trypanosomiasis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Incuron LLC
    Novartis AG
    Sanofi
    Scynexis Inc

    Request for Sample

    Report Url http://www.reportsweb.com//african-trypanosomiasis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//african-trypanosomiasis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//african-trypanosomiasis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments